1 Result: Annexon
Disappointing Results in Mirati Therapeutics' SAPPHIRE Study and Annexon's ARCHER Trial Lead to Stock Declines
May 24th, 2023
Mirati Therapeutics, Inc. (Nasdaq: MRTX) revealed disappointing news regarding the SAPPHIRE study, as it failed to meet its primary goal of overall survival in the final analysis. The Phase 3 study aimed to assess the effectiveness of sitravatinib, i. Read more
Load More Content
Want To Find Some News?
News By Industries
Recent Post
-
Johnson & Johnson, Charles Schwab, Halliburton: Earnings Preview
January 18th, 2026Key Earnings Ahead for Netflix, Fastenal, and U.S. Bancorp
January 18th, 2026Louisville Thunder Appoints Veteran Coach Mike Reed to Lead Program
January 15th, 2026FDA Approves First Treatment for Children With Menkes Disease
January 13th, 2026
Member Login